Alteogen Inc
KOSDAQ:196170

Watchlist Manager
Alteogen Inc Logo
Alteogen Inc
KOSDAQ:196170
Watchlist
Price: 457 000 KRW -0.22% Market Closed
Market Cap: 24.5T KRW

Alteogen Inc
Net Income (Common)

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Alteogen Inc
Net Income (Common) Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Net Income (Common) CAGR 3Y CAGR 5Y CAGR 10Y
Alteogen Inc
KOSDAQ:196170
Net Income (Common)
₩94.3B
CAGR 3-Years
249%
CAGR 5-Years
60%
CAGR 10-Years
77%
Celltrion Inc
KRX:068270
Net Income (Common)
₩737.8B
CAGR 3-Years
8%
CAGR 5-Years
8%
CAGR 10-Years
20%
SK Bioscience Co Ltd
KRX:302440
Net Income (Common)
-₩53.9B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
V
Voronoi Inc
KOSDAQ:310210
Net Income (Common)
-₩32.6B
CAGR 3-Years
-29%
CAGR 5-Years
8%
CAGR 10-Years
N/A
P
PharmaResearch Co Ltd
KOSDAQ:214450
Net Income (Common)
₩127B
CAGR 3-Years
44%
CAGR 5-Years
41%
CAGR 10-Years
28%
A
ABL Bio Inc
KOSDAQ:298380
Net Income (Common)
-₩20.5B
CAGR 3-Years
22%
CAGR 5-Years
7%
CAGR 10-Years
N/A
No Stocks Found

Alteogen Inc
Glance View

Market Cap
24.4T KRW
Industry
Biotechnology

In the bustling hub of South Korea's biotech industry, Alteogen Inc. has carved out a distinctive niche with its innovative approach to drug development. Founded in 2008, this company has harnessed the power of advanced biotechnology to specialize in the development of biopharmaceuticals, particularly focusing on creating long-acting protein therapeutics and biobetters. Alteogen's flagship technology, ALT-P7, a proprietary platform for producing antibody-drug conjugates, exemplifies how the company blends scientific ingenuity with commercial acumen. By reimagining existing biological drugs known as biobetters, Alteogen leverages its proprietary technologies to improve the efficacy and delivery of these treatments, promising enhanced convenience and therapeutic outcomes for patients. Financially, Alteogen thrives through both strategic partnerships and its own product pipeline. The company secures revenue by licensing its technology platforms to global pharmaceutical giants, thereby earning milestone payments and royalties. Additionally, Alteogen's ongoing research and development efforts continuously expand its portfolio, particularly in biosimilars—biological products highly similar to already-approved reference products. This dual-pronged approach, combining its proprietary biotechnological innovations with robust strategic alliances, positions Alteogen not just as a player but as an innovator in the biopharmaceutical sector, with the potential for significant impact in the realm of chronic disease treatment.

Alteogen Inc Intrinsic Value
HIDDEN
Show

See Also

What is Alteogen Inc's Net Income (Common)?
Net Income (Common)
94.3B KRW

Based on the financial report for Jun 30, 2025, Alteogen Inc's Net Income (Common) amounts to 94.3B KRW.

What is Alteogen Inc's Net Income (Common) growth rate?
Net Income (Common) CAGR 10Y
77%

The average annual Net Income (Common) growth rates for Alteogen Inc have been 249% over the past three years , 60% over the past five years , and 77% over the past ten years .

Back to Top